Radio-iodine therapy in differentiated thyroid cancer: indications and procedures

Post-surgical ablative iodine-131 therapy is recommended for all differentiated thyroid cancer primary tumors >1cm in diameter. Regarding smaller primary tumors, ¹³¹I ablation may be helpful in special cases: tumor close to the thyroid capsule, previous percutaneous radiation to the neck, familial occurrence of thyroid cancer, tumor diameter 5–10mm, and unfavorable histological variants. In this context, the patient's preferences for safety should be considered. In most centers, standard fixed activities of 1–3 GBq are used for ¹³¹I ablation. Preparation for the procedure with such activities requires a low-iodine diet for 2–3 weeks and stimulation of thyroid stimulating hormone (TSH) by withholding of thyroid hormone for 3 weeks following thyroidectomy or by use of recombinant human TSH. The advantages of recombinant TSH are avoidance of hypothyroid morbidity and consequently a better quality of life, as well as a lower radiation dose to extra-thyroidal compartments. To treat metastastic differentiated thyroid cancer, higher activities of radio-iodine (in the range 4–11 GBq) are necessary; if possible, individual dosimetry is recommended. The standard approach to preparation for ¹³¹I therapy in patients with metastases is endogenous hypothyroidism after thyroid hormone withdrawal.

Key words: differentiated thyroid cancer, radio-iodine therapy, dosimetry, side-effects, recombinant human thyrotropin, guidelines